Amantadine Related Published Studies
Well-designed clinical trials related to Amantadine
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. [2011.05.17]
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. [2010.12.31]
Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. [2010.12.08]
Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. [2010.11]
Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. [2010.11]
Pathological gambling in Parkinson disease is reduced by amantadine. [2010.09]
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. [2010.09]
Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. [2010.01]
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. [2010]
Effects of amantadine on tardive dyskinesia: a randomized, double-blind,
placebo-controlled study. [2010]
Pathological gambling in Parkinson disease is reduced by amantadine. [2010]
Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis? [2009.09]
Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. [2009.07]
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. [2008.11]
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. [2008.06.19]
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. [2007.08]
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study. [2007.07.28]
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. [2007.05]
Effect of early administration of the N-methyl-d-aspartate receptor antagonist amantadine on the development of postmastectomy pain syndrome: a prospective pilot study. [2007.03]
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. [2007.02]
Modulation of human motor cortex excitability by single doses of amantadine. [2006.12]
Effect of Early Administration of the N-Methyl-D-Aspartate Receptor Antagonist Amantadine on the Development of Postmastectomy Pain Syndrome: A Prospective Pilot Study. [2006.09.20]
Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. [2006.05]
Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. [2006.04]
Amantadine sulfate reduces experimental sensitization and pain in chronic back pain patients. [2006.03]
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). [2006.03]
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. [2006.02]
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. [2006.01]
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. [2005.11]
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. [2005.11]
Placebo-controlled trial of amantadine in multiple-system atrophy. [2005.09]
Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. [2005.09]
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. [2005.09]
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. [2005.05]
Effect of amantadine on motor memory consolidation in humans. [2005.03]
Amantadine for weight gain associated with olanzapine treatment. [2005.01]
Well-designed clinical trials possibly related to Amantadine
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. [2012]
Donepezil and memantine for moderate-to-severe Alzheimer's disease. [2012]
Memantine and functional communication in Alzheimer's disease: results of a
12-week, international, randomized clinical trial. [2012]
Pharmacologic treatment for memory disorder in multiple sclerosis. [2011.10.05]
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. [2011.10]
Lack of evidence for the efficacy of memantine in mild Alzheimer disease. [2011.08]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]
Milestones in Parkinson's disease therapeutics. [2011.05]
Effect of memantine on resting state default mode network activity in Alzheimer's disease. [2011.03.01]
Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. [2011.03]
[Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. [2011.02.01]
Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects. [2011.02]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. [2011.02]
A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. [2011.01]
Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial):
study protocol for a randomized controlled trial. [2011]
On the promise of pharmacotherapies targeted at cognitive and neurodegenerative
components of Down syndrome. [2011]
Memantine for non-motor features of Parkinson's disease: a double-blind placebo
controlled exploratory pilot trial. [2011]
Memantine in behavioral variant frontotemporal dementia: negative results. [2011]
Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease. [2010.11]
The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. [2010.10]
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. [2010.10]
NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. [2010.10]
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. [2010.10]
A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. [2010.09.01]
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. [2010.06]
Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. [2010.05]
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. [2010.03]
Carnitine for fatigue in multiple sclerosis. [2010.02.17]
A randomized trial of memantine as treatment for spasticity in multiple sclerosis. [2010.02]
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. [2010.02]
Memantine for AIDS dementia complex: open-label report of ACTG 301. [2010.01]
A randomized, placebo-controlled trial of memantine for functional disability in
amyotrophic lateral sclerosis. [2010]
Memantine for cognitive impairment in multiple sclerosis: a randomized
placebo-controlled trial. [2010]
Memantine for AIDS dementia complex: open-label report of ACTG 301. [2010]
Effectiveness of medications used to attenuate antipsychotic-related weight gain
and metabolic abnormalities: a systematic review and meta-analysis. [2010]
Clinical and basal aspects of anemia during antiviral therapy for hepatitis C. [2009.10]
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. [2009.10]
Current Alzheimer's disease clinical trials: methods and placebo outcomes. [2009.09]
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. [2009.07.24]
Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. [2009.07]
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. [2009.07]
Efficacy and safety of memantine in Lewy body dementia. [2009.07]
Randomized controlled trial of memantine in dementia associated with Parkinson's disease. [2009.06.15]
The effects of memantine on prepulse inhibition. [2009.06]
Memantine induces reversible neurologic impairment in patients with MS. [2009.05.12]
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. [2009.05]
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. [2009.04]
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. [2009.03.28]
Memantine for prophylaxis of chronic tension-type headache--a double-blind, randomized, crossover clinical trial. [2009.03]
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. [2008.12]
Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy. [2008.10.15]
Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. [2008.10.03]
[Observation on therapeutic effect of low energy He-Ne laser acupoint radiation on infantile cold] [2008.09]
Blocking NMDA receptor signaling does not decrease hormonal counterregulation to hypoglycemia in humans. [2008.09]
Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial. [2008.09]
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. [2008.08.15]
A 6-month, open-label study of memantine in patients with frontotemporal dementia. [2008.07]
[Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil] [2008.07]
Tinnitus treatment with memantine. [2008.04]
Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. [2008.04]
Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. [2008.03]
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. [2008.03]
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. [2008.02]
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. [2008.02]
The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. [2008]
|
